OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Schilling on Screening for Breast Cancer

March 4th 2015

Kathy Schilling, MD, radiologist, Christine E. Lynn Women's Health & Wellness Institute at Boca Raton Regional Hospital, discusses screening methods for breast cancer.

Dr. Kunz on Anticipated Trial Results for Patients with Neuroendocrine and Carcinoid Tumors

March 4th 2015

Pamela L. Kunz, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses some anticipated trial results for patients with neuroendocrine and carcinoid tumors.

Dr. Randy Gascoyne on Biomarkers for Follicular Lymphoma

March 3rd 2015

Randy Gascoyne, MD, hematopathologist and research director for the Centre for Lymphoid Cancers at the BC Cancer Agency in Canada, discusses a study that investigated biomarkers for follicular lymphoma.

Dr. Wakelee on Proteomic Testing in Non-Small Cell Lung Cancer

March 3rd 2015

Heather Wakelee, MD, associate professor of medicine, oncology division, Stanford University Medical Center, discusses VeriStrat testing for patients with non-small cell lung cancer.

Dr. Kipps on Ibrutinib and Idelalisib For CLL

February 25th 2015

Thomas Kipps, MD, PhD, Division of Hematology-Oncology Deputy Director for Research at the UC San Diego Moores Cancer Center, discusses the mechanisms of ibrutinib and idelalisib for the treatment of chronic lymphocytic leukemia (CLL).

Dr. Horwitz on the Challenges With T-Cell Lymphoma

February 25th 2015

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the challenges oncologists face with T-cell lymphoma.

Dr. Cremolini on Identifying Molecular Markers in mCRC

February 25th 2015

Chiara Cremolini, MD, a medical oncologist at the Tuscan Tumor Institute in Pisa, Italy, discusses the necessary steps researchers must take to identify molecular markers in metastatic colorectal cancer (mCRC).

Dr. Edith Perez on BOLERO-1 Results in HER2-Positive Breast Cancer

February 24th 2015

Edith Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, compares the results of the BOLERO-1 and BOLERO-3 trials.

Jim Feldman on the Importance of Social Networking for Urologists

February 24th 2015

Jim Feldman, chief innovative officer, Shift Happens, discusses change management for urologists and why it is important for them to have a social media presence.

Dr. Jonathan Henderson Discusses the Professional Need and Business Model for Men's Health Clinics

February 20th 2015

Jonathan Henderson, MD, urologist, Regional Urology, assistant director of clinical research, discusses how men's health clinics should be run by urologists.

Dana Jacoby on How a Group of Physicians Can Become a Successful Medical Group

February 19th 2015

Dana Jacoby, senior consultant, BSM Consulting, gives advice on how a group of physicians can build a strong, healthy culture when looking to form a successful medical organization.

Bob Asinof on Recruiting Physicians to Private Centers

February 18th 2015

Bob Asinof, chief executive officer of The Urology Center of Colorado, discusses the challenges of recruiting urologists to their center while competing with larger cancer centers and hospital systems.

Dr. Matthew Davids On Advances in CLL

February 18th 2015

Matthew Davids, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, talks about advances in chronic lymphocytic leukemia (CLL) treatment.

Dr. Walsh Compares Open and Robotic-Assisted Radical Prostatectomy Operations

February 18th 2015

Patrick C. Walsh, MD, university distinguished service professor of urology, Johns Hopkins School of Medicine, discusses radical prostatectomy operations in the traditional open and robotic-assisted form.

Dr. Brahmer on Immunotherapy Development in Lung Cancer

February 17th 2015

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses immunotherapy and how it can advance as a treatment option for patients with lung cancer.

Dr. Wright on Measuring Progression and Recurrence in Ovarian Cancer

February 16th 2015

Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses the challenges in measuring progression and recurrence in patients with ovarian cancer.

Dr. Marcia Brose Discusses Lenvatinib as a New Option in DTC

February 13th 2015

Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses lenvatinib as a new treatment option for patients with radioactive iodine-refractory differentiated thyroid cancer.

Dr. Topalian on Biomarkers for Anti- PD-1 Therapies in Melanoma

February 12th 2015

Suzanne Topalian, MD, professor of surgery and oncology, John Hopkins Medicine, and director of the melanoma program, Sidney Kimmel Comprehensive Cancer Center, compares biomarker detection for anti- PD-1 therapies like nivolumab to anti-CTLA-4 therapies like ipilimumab for the treatment of melanoma.

Dr. Peter Carroll on Reducing Unnecessary Biopsies in Prostate Cancer

February 10th 2015

Peter R. Carroll, MD, MPH, professor and chair of the Department of Urology, University of California San Francisco, talks about the future of biomarker-based testing for prostate cancer.

Dr. Finn Discusses Palbociclib for Patients With Advanced Breast Cancer

February 10th 2015

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses findings from a phase II PALOMA-1/TRIO-18 study that examined palbociclib in combination with letrozole as a first-line treatment with ER-positive, HER2-negative, advanced breast cancer.